Tronvik Erling, Stovner Lars J, Bovim Gunnar, White Linda R, Gladwin Amanda J, Owen Kathryn, Schrader Harald
Department of Neurosciences, Norwegian University of Science and Technology, Trondheim, Norway.
BMC Neurol. 2008 Mar 26;8:4. doi: 10.1186/1471-2377-8-4.
The main objective of this study was to investigate the angiotensin converting enzyme (ACE) genotype as a possible risk factor for migraine (both with and without aura) compared to controls. We also wanted to examine whether a clinical response to an ACE inhibitor, lisinopril, or an angiotensin II receptor blocker, candesartan, in migraine prophylaxis was related to ACE genotype.
347 migraine patients aged 18-68 (155 migraine without aura (MoA), 187 migraine with aura (MwA) and 5 missing aura subgroup data) and 403 healthy non-migrainous controls > 40 years of age were included in the study. A polymerase chain reaction (PCR) was performed on the genomic DNA samples to obtain the ACE insertion (I)/deletion(D) polymorphisms.
No significant differences between migraine patients and controls were found with regard to ACE genotype and allele distributions. Furthermore, there was no significant difference between the controls and the MwA or MoA subgroups.
In our sample there is no association between ACE genotype or allele frequency and migraine. In addition, ACE genotype in our experience did not predict the clinical response to lisinopril or candesartan used as migraine prophylactics.
本研究的主要目的是调查血管紧张素转换酶（ACE）基因型与对照组相比，是否为偏头痛（有无先兆）的可能危险因素。我们还想研究偏头痛预防性治疗中，对ACE抑制剂赖诺普利或血管紧张素II受体阻滞剂坎地沙坦的临床反应是否与ACE基因型有关。
本研究纳入了347名年龄在18 - 68岁的偏头痛患者（155名无先兆偏头痛（MoA）患者，187名有先兆偏头痛（MwA）患者，5名缺失先兆亚组数据）和403名年龄大于40岁的健康非偏头痛对照者。对基因组DNA样本进行聚合酶链反应（PCR）以获得ACE插入（I）/缺失（D）多态性。
在ACE基因型和等位基因分布方面，偏头痛患者与对照者之间未发现显著差异。此外，对照组与MwA或MoA亚组之间也没有显著差异。
在我们的样本中，ACE基因型或等位基因频率与偏头痛之间没有关联。此外，根据我们的经验，ACE基因型不能预测用作偏头痛预防性治疗的赖诺普利或坎地沙坦的临床反应。
